Blandine Mondésert, MD, Paul Khairy, MD, PhD, Gernot Schram, MD, PhD, Azadeh Shohoudi, PhD, Mario Talajic, MD, Jason G. Andrade, MD, Marc Dubuc, MD, FHRS, Peter G. Guerra, MD, FHRS, Laurent Macle, MD, FHRS, Denis Roy, MD, FHRS, Katia Dyrda, MD, Bernard Thibault, MD, FHRS, Miguel Barrero, MD, Ariel Diaz, MD, Simon Kouz, MD, Serge McNicoll, MD, Dominika Nowakowska, MD, Léna Rivard, MD, MSccorrespondenceemail
The purpose of this study was to determine the impact of revascularization on recurrent VAs or death.
A cohort study was conducted on consecutive patients with prior myocardial infarction and LVEF ≥40% presenting with a first clinical sustained VA in the absence of an acute coronary syndrome. The impact of revascularization on recurrent VAs and all-cause mortality was assessed.
A total of 274 patients (mean age 66.1 ± 9.7 years, 85.4% male, mean LVEF 48.3% ± 7.2%) were included in the study. Eight-eight patients (32.1%) underwent coronary revascularization. During mean follow-up of 6.2 ± 5.1 years, 140 (51.1%) died or had recurrent sustained VAs or appropriate implantable-cardioverter defibrillator therapy. Revascularization was not associated with a significantly lower rate of recurrent VAs or death (multivariable hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.60–1.24, P = .43) regardless of whether it was complete or incomplete (HR 0.65, 95% CI 0.25–1.69, P = .37) or was performed by percutaneous or surgical means (HR 1.02, 95% CI 0.53–1.94, P = .96). An implantable-cardioverter defibrillator was associated with a significant reduction in mortality (HR 0.23, 95% CI 0.09–0.55, P = .001).
Patients with prior myocardial infarction and LVEF ≥40% who present with sustained VAs in the absence of an acute coronary syndrome remain at high risk for recurrent VAs and all-cause death. Coronary revascularization does not systemically mitigate this risk.